The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology

Edward C. Stites^*

Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, AZ 85004, USA.

Present address: Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.

Abstract: The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy. However, this same agent does not generally benefit colon cancer patients who have the BRAF(V600E) mutation. Recent work suggests that BRAF(V600E) inhibition by vemurafenib results in decreased negative feedback to the epidermal growth factor receptor (EGFR) pathway and that the different clinical responses are due to differences in the amount of EGFR present in these two cancers. The experimental work that identified the feedback signaling was an elegant mix of functional genomic approaches and focused, hypothesis-driven cellular and molecular biology. The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers with both vemurafenib and EGFR inhibitors is worth clinical evaluation.

* Corresponding author. E-mail: estites{at}tgen.org

The editors suggest the following Related Resources on Science sites:

In Science Signaling

PERSPECTIVES
Cancer
The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment

Michael B. Yaffe (2 April 2013)
Sci. Signal. 6 (269), pe13. [DOI: 10.1126/scisignal.2003684]
 |  Abstract »  |  Full Text »  |  PDF »

RESEARCH ARTICLES
Cell Biology
ERK-Mediated Phosphorylation of Fibroblast Growth Factor Receptor 1 on Ser⁷⁷⁷ Inhibits Signaling

Malgorzata Zakrzewska, Ellen Margrethe Haugsten, Beata Nadratowska-Wesolowska, Angela Oppelt, Barbara Hausott, Yixin Jin, Jacek Otlewski, Jørgen Wesche, and Antoni Wiedlocha (12 February 2013)
Sci. Signal. 6 (262), ra11. [DOI: 10.1126/scisignal.2003087]
 |  Editor's Summary »  |  Abstract »  |  Full Text »  |  PDF »  |  Supplementary Materials »

PODCASTS
Cancer
Science Signaling Podcast: 29 January 2013

Friedegund Meier and Annalisa M. VanHook (29 January 2013)
Sci. Signal. 6 (260), pc3. [DOI: 10.1126/scisignal.2003968]
 |  Abstract »  |  Full Text »  |  Podcast »

RESEARCH ARTICLES
Cancer
Vemurafenib Potently Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in BRAFV600E Melanoma Cells

Daniela Beck, Heike Niessner, Keiran S. M. Smalley, Keith Flaherty, Kim H. T. Paraiso, Christian Busch, Tobias Sinnberg, Sophie Vasseur, Juan Lucio Iovanna, Stefan Drießen, Björn Stork, Sebastian Wesselborg, Martin Schaller, Tilo Biedermann, Jürgen Bauer, Konstantinos Lasithiotakis, Benjamin Weide, Jürgen Eberle, Birgit Schittek, Dirk Schadendorf, Claus Garbe, Dagmar Kulms, and Friedegund Meier (29 January 2013)
Sci. Signal. 6 (260), ra7. [DOI: 10.1126/scisignal.2003057]
 |  Editor's Summary »  |  Abstract »  |  Full Text »  |  PDF »  |  Supplementary Materials »

EDITORIAL GUIDES
Medicine
2012: Signaling Breakthroughs of the Year

Michael B. Yaffe and Nancy R. Gough (1 January 2013)
Sci. Signal. 6 (256), eg1. [DOI: 10.1126/scisignal.2003881]
 |  Abstract »  |  Full Text »  |  PDF »

EDITORS' CHOICE
Cancer
Redundantly Resistant to Therapy

Ernesto Andrianantoandro (31 July 2012)
Sci. Signal. 5 (235), ec199. [DOI: 10.1126/scisignal.2003448]
 |  Abstract »

RESEARCH RESOURCES
Cancer
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma

Kris C. Wood, David J. Konieczkowski, Cory M. Johannessen, Jesse S. Boehm, Pablo Tamayo, Olga B. Botvinnik, Jill P. Mesirov, William C. Hahn, David E. Root, Levi A. Garraway, and David M. Sabatini (15 May 2012)
Sci. Signal. 5 (224), rs4. [DOI: 10.1126/scisignal.2002612]
 |  Editor's Summary »  |  Abstract »  |  Full Text »  |  PDF »  |  Supplementary Materials »

RESEARCH ARTICLES
Cancer
Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Scott Newman, Jonathan R. Dry, Mark Hampson, Paul A. W. Edwards, Paul D. Smith, and Simon J. Cook (29 March 2011)
Sci. Signal. 4 (166), ra17. [DOI: 10.1126/scisignal.2001752]
 |  Editor's Summary »  |  Abstract »  |  Full Text »  |  PDF »  |  Supplementary Materials »

PERSPECTIVES
Cancer
Resistance to MEK Inhibitors: Should We Co-Target Upstream?

Poulikos I. Poulikakos and David B. Solit (29 March 2011)
Sci. Signal. 4 (166), pe16. [DOI: 10.1126/scisignal.2001948]
 |  Abstract »  |  Full Text »  |  PDF »

EDITORIAL GUIDES
Cancer
Focus Issue: Rendering Resistance Futile

Elizabeth M. Adler and Nancy R. Gough (29 March 2011)
Sci. Signal. 4 (166), eg3. [DOI: 10.1126/scisignal.2002014]
 |  Abstract »  |  Full Text »  |  PDF »

RESEARCH ARTICLES
Cancer
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

Ryan B. Corcoran, Dora Dias-Santagata, Kristin Bergethon, A. John Iafrate, Jeffrey Settleman, and Jeffrey A. Engelman (23 November 2010)
Sci. Signal. 3 (149), ra84. [DOI: 10.1126/scisignal.2001148]
 |  Editor's Summary »  |  Abstract »  |  Full Text »  |  PDF »  |  Supplementary Materials »